Access

Format

Author / Creator

Subject

Recently added

Eresources

Language

Place of Publication

Dates

Location

Population dynamics in ecological space and time / edited by Olin E. Rhodes, Jr., Ronald K. Chesser, and Michael H. Smith.

195 - Z/SP/P6/190a - Rose Hill Heights - [Illustrated advertising pamphlet], 1885

153 - Z/SP/P6/151 - Group 89 Block Plan - Fullagar's Estate, May's Hill Parramatta - Western Rd, Fullagar Rd, 1920

008 - Z/SP/P6/8 - 6 Villa Portions Parramatta Park - Government Rd, Carriage Rd

[Parramatta subdivision plans] [cartographic material]

BackgroundHigh-grade gliomas including glioblastoma (GBM) and diffuse midline gliomas (DMG) represent the most lethal and aggressive brain cancers where current treatment modalities offer limited efficacy. Chimeric antigen receptor (CAR) T cell therapies have emerged as a promising strategy, boasting tumor-specific targeting and the unique ability to penetrate the blood-brain barrier. However, the effective clinical application hinges on the optimal choice of antigen, with a limited number, currently under investigation.MethodsWe employed cell surface proteomic analysis of primary human high-grade glioma samples from both adult and pediatric patients. This led to the identification of Ephrin type-A receptor 3 (EphA3) as a prevalently expressed target. We engineered a second-generation EphA3-targeted CAR T cell and assessed function using in vitro and in vivo models of GBM and DMG.ResultsEphA3-targeted CAR T cells demonstrated robust antigen-specific killing of human GBM and DMG cell lines in vitro. In an orthotopic xenograft NSG mouse model, EphA3-targeted CAR T cells not only effectively eradicated tumors but also established a functional T cell population protective on rechallenge. Remarkably, mice rechallenged with a second contralateral orthotopic tumor implantation achieved complete tumor clearance and maintained a sustained complete response 6 months following initial treatment.ConclusionBuilding on the proven safety profile of EphA3 antibodies in clinical settings, our study provides compelling preclinical evidence supporting the efficacy of EphA3-targeted CAR T cells against high-grade gliomas. These findings underscore the potential for transitioning this innovative therapy into clinical trials, aiming to revolutionize the treatment landscape for patients afflicted with these formidable brain cancers.

Journal for immunotherapy of cancer, 2024-08, Vol.12 (8), p.e009486

EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses

Export record to excel

Export this record

Export record to excel

Population dynamics in ecological space and time / edited by Olin E. Rhodes, Jr., Ronald K. Chesser, and Michael H. Smith.

Export this record

Export record to excel

[Parramatta subdivision plans] [cartographic material]

Export this record

Export record to excel

EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses

Refine your search